AstraZeneca

Open: 67.4 Close: 66.31 Change: -1.09

Can you guess what an AI found about AstraZeneca.

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, rare, disease, pipeline, buy, drug, Amolyt, and the most common words in the summary are: astrazeneca, news, pharma, rare, disease, amolyt, company, . One of the sentences in the summary was: AstraZeneca to buy amolyt pharma for $1.05b to expand rare disease pipeline. Other searches …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

AstraZeneca to buy amolyt pharma for $1.05b to expand rare disease pipeline. Anglo-Swedish pharmaceuticals giant is expanding further into the field of rare drugs.

Today's News

AstraZeneca to buy amolyt pharma for $1.05b to expand rare disease pipeline. AZ&Me™ is designed to help qualifying people without insurance and those on Medicare who are having trouble affording their AstraZeneca medications. AstraZecas is one of several pharmaceutical companies participating in a prescription drug discount program. AstraZeneca will buy Amolyt Pharma for a total consideration of up to $1.05 billion, on a cash and debt free basis. The proposed acquisition will bolster the Alexion, Astra Zeneca Rare Disease late-stage pipeline. AstraZeneca to invest 650 million pounds in UK to boost pandemic preparedness. FDA approves Astra-Sanofis RSV therapy highly effective against infant hospitalizations, CDC study shows Astra Zeneca and Sanofis antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV) AstraZeneca to buy French biotech specialist Amolyt Pharma for about $1 billion. Anglo-Swedish pharmaceuticals giant is expanding further into the field of rare drugs. AstraZeneca has grown its annual rare diseases revenue to nearly $7.8 billion with the help of other recent deals, beginning with the $39 billion acquisition. AstraZeneca acquires Amolyt Pharma in a $1.05 billion deal to bag its rare disease-focused pipeline. Eneboparatide, a treatment for hypoparathyroidism in late-stage development and other promising drugs in Amolyts pipeline. AstraZenecas rare disease portfolio generated $7.76bn in global sales in 2023. Amolyts lead candidate, eneboparatide (AZP-3601), was a central part of the acquisition. Despite this, Astra has seen some success amongst rare diseases not cancer-related. AstraZeneca has several key R&D, manufacturing and commercial locations across the United States, including in Boston, MA.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, rare, disease, pipeline, buy, drug, Amolyt, and the most common words in the summary are: astrazeneca, news, pharma, rare, disease, amolyt, company, . One of the sentences in the summary was: AstraZeneca to buy amolyt pharma for $1.05b to expand rare disease pipeline. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #news #pharma #rare #disease #amolyt #company.